Despite getting off to a sluggish start five years ago, SGLT2 inhibitors are steadily picking up steam thanks to buoyant sales of their combination medicines with DPP-4 inhibitors. Even monodrugs alone grew 29% in FY2018, with the market including the…
HOME > TRENDS
TRENDS
-
Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
-
Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
May 21, 2018
-
Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
-
Lilly Japan Joins Top 10 List for 1st Time, Sales Triple in 10 Years on Successive Launches
March 30, 2018
-
Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
-
Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
February 23, 2018
-
With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
February 8, 2018
-
Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
November 22, 2017
-
21 Drug Makers Expect 1.6% Increase in Sales but Decline in Profits in FY2017
November 15, 2017
-
Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015
September 26, 2017
-
Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?
September 5, 2017
-
Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
August 22, 2017
-
Pharmas’ Rep Number Corrections in Full Force amid Bleak Market Outlook, Silver Lining Seen in “Specialty” Arena
August 18, 2017
-
Top Drugs Jostling for Higher Share amid Tepid Market, Trulicity Overtakes Victoza in GLP Space: April-June
August 7, 2017
-
Japan Sales of Global Pharmas Dipped in 2016? Price Cuts, Sluggish LLPs Weighs: Jiho Tally
June 28, 2017
-
Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
Japan Pharma Earnings Show SGLT-2 Market Uptake Still Slow
May 22, 2017
-
Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
-
Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…